6月23日，生物制药公司药捷安康-B（02617.HK）在港交所主板挂牌上市，股价表现强劲。盘中，该股大涨63.12%，引发市场广泛关注。
药捷安康-B此次IPO反应热烈。公司公开发售部分获得约3420倍超额认购，显示投资者对其前景充满信心。公司以每股13.15港元的价格发行1528.1万股，募集资金总额约2.01亿港元。值得注意的是，一手（500股）中签率仅为0.8%，反映出散户投资者的踊跃参与。
作为一家专注于小分子创新药物开发的公司，药捷安康主要致力于肿瘤、炎症及心脏代谢疾病领域的治疗。公司核心产品Tinengotinib是一种处于注册临床阶段的MTK抑制剂，可用于治疗多种复发或难治性实体瘤。投资者看好公司在生物制药领域的创新能力和市场潜力，推动其股价在上市首日大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.